0
₹0 0
Nextgen Biotech

Call us:

menu

Dauneon 20mg - Daunorubicin Injection

  • Home
  • Dauneon 20mg - Daunorubicin Injection

Dauneon 20mg - Daunorubicin Injection

Dauneon 20mg is a chemotherapy injection used primarily for the treatment of leukemias, especially acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). It works by interfering with the DNA replication process in cancer cells, leading to their destruction.

Choose Quantity:

-
+
+ Add To Cart
Add to wishlist
Share
Description Product Details
General Information:
Generic Name: Daunorubicin Hydrochloride
Brand Name: Dauneon 20mg
Packing: Vial
Strength: 20 mg/vial
Manufacturer: Neon Laboratories Ltd.
Form: Injection (Lyophilized Powder for Reconstitution)
Category: Anticancer / Anthracycline Antibiotic / Chemotherapy
Product Introduction:
Dauneon 20mg contains Daunorubicin Hydrochloride, an anthracycline-class cytotoxic antibiotic. It is administered intravenously and forms a core part of combination chemotherapy regimens in hematological cancers. Daunorubicin is highly effective due to its strong DNA-binding ability and topoisomerase II inhibition.
Uses:
Dauneon 20mg is used for the treatment of:
  1. Acute Myeloid Leukemia (AML)
  2. Acute Lymphoblastic Leukemia (ALL)
  3. Blastic Phase of Chronic Myeloid Leukemia (CML)
  4. Other hematological malignancies (in combination therapy)
  5. Induction and consolidation phases of leukemia treatment
  6. Treatment protocols including the “7+3” regimen (cytarabine + daunorubicin)
Storage Instructions:
  1. Store between 2°C to 8°C (Refrigerated)
  2. Protect from light and do not freeze
  3. Reconstituted solution should be used immediately or stored as per manufacturer’s instructions
  4. Keep out of reach of children
How It Works (Mechanism of Action):
Daunorubicin intercalates into DNA base pairs, inhibiting topoisomerase II, an enzyme needed for DNA repair and replication. It also generates free radicals that cause DNA strand breaks, leading to cell cycle arrest and apoptosis (cell death) in rapidly dividing cancer cells.
Side Effects:
Common side effects:
  1. Nausea and vomiting
  2. Hair loss (alopecia)
  3. Fatigue and weakness
  4. Mouth sores (mucositis)
  5. Bone marrow suppression (low WBC, RBC, platelets)
  6. Red discoloration of urine (harmless)
Severe side effects:
  1. Cardiotoxicity (congestive heart failure, arrhythmias) – dose-dependent
  2. Severe myelosuppression
  3. Liver enzyme abnormalities
  4. Extravasation reactions (tissue damage at injection site)
  5. Secondary malignancies (with prolonged use)
Dosage (Typical Recommended Dose):
  1. Adult AML induction: 45–60 mg/m²/day IV for 3 days, often with cytarabine for 7 days (7+3 regimen)
  2. Doses are adjusted based on patient factors such as age, organ function, and bone marrow reserve
  3. Cumulative lifetime dose should not exceed 550 mg/m² due to risk of cardiotoxicity
Method of Administration:
  1. Intravenous (IV) infusion only
  2. Administered by trained medical professionals in a clinical setting
  3. Should not be given intramuscularly, subcutaneously, or intrathecally
  4. Avoid extravasation – administer slowly and monitor site during infusion
Precautions:
  1. Perform baseline and periodic cardiac function tests (e.g., ECG, LVEF)
  2. Monitor complete blood counts, liver and kidney function regularly
  3. Not recommended during pregnancy unless essential – can harm the fetus
  4. Use effective contraception during treatment
  5. Avoid live vaccines and people with infections
  6. Dose adjustments may be needed in hepatic impairment
Drug Interactions:
  1. Cyclophosphamide, trastuzumab, or other cardiotoxic agents – increased heart toxicity risk
  2. Concurrent use with radiation may increase tissue damage
  3. Live vaccines (e.g., BCG, MMR) should be avoided
  4. CYP450 inducers/inhibitors may affect drug levels – consult doctor before adding new medications
Allergies:
  1. Contraindicated in patients with known hypersensitivity to daunorubicin or other anthracyclines
  2. Watch for signs of anaphylaxis, rash, fever, or breathing difficulty
Overdose Information:
  1. Overdose may cause severe bone marrow suppression, heart failure, mucositis, and liver damage
  2. No specific antidote – manage with intensive supportive care and monitoring
  3. Seek emergency medical attention if overdose is suspected
Missed Dose Instructions:
  1. As it is administered in a clinical setting, missed doses are handled by healthcare providers
  2. Notify your medical team if an appointment or infusion is missed for rescheduling
Additional Notes:
  1. Cardiac toxicity is dose-related and irreversible, so lifetime cumulative dose must be monitored
  2. Inform patients about possible red-colored urine post-infusion (not harmful)
  3. Use central line when possible to minimize risk of tissue necrosis from extravasation
  4. Should only be used under the supervision of an oncologist or trained cancer specialist
View More

In The Same Category

Cart